Protease for activating clotting factor VII

US6528299B1 · kind B1 · utility

Assignee

• Aventis Behring GmbH · DE

Inventors

• Jürgen Römisch · Marburg, DE
• Annette Feussner · Marburg, DE
• Hans-Arnold Stohr · Wetter, DE

Key dates

• Filing date: Apr 21, 1999
• Grant date: Mar 4, 2003
• Expiry date: Apr 21, 2019

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/96447
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin.